Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
25 participants
INTERVENTIONAL
2012-04-30
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurotrophic Factors and Depression
NCT00812994
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
NCT00183677
An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms
NCT01814098
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Escitalopram
Escitalopram 10 mg/d to 20 mg/d
Escitalopram
escitalopram 10 mg/d to 20 mg/d
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Escitalopram
escitalopram 10 mg/d to 20 mg/d
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 20-65
3. Drug-naive
4. Hamilton Depression Rating Scale exceeding 14 scores
Exclusion Criteria
2. Substance use
3. Pregnant
4. Allergy to escitalopram
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beitou Armed Forces Hospital, Taipei, Taiwan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peishen Ho, M.D.
Role: STUDY_CHAIR
Beitou Armed Forces Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beitou Armed Forces Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BAFH
Identifier Type: OTHER
Identifier Source: secondary_id
BAFH-101-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.